INmune Bio logo
INmune Bio
INMB | NASDAQ
Chart Builder DCF Calculator
$0.95
-$0.10 (-9.52%)
At close: Nov 16, 2026, 4:00 PM ET
$0.95
$0.00 (-0.38%)
After-hours: Nov 16, 2026, 7:30 PM ET

INmune Bio Company Profile

Company profile explained

Company Profile

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

Key Executives

Name Position
David J. Moss President, Chief Executive Officer, Treasurer, Secretary & Director
Cory Randall Ellspermann Interim Chief Financial Officer
Daniel Frederick Carlson Head of Investor Relations
Joshua S. Schoonover General Counsel
Mark William Lowdell Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 29, 2026 424B5 Filing
Oct 21, 2026 8-K Current Report
Sep 23, 2026 4 Filing
Sep 23, 2026 3 Filing
Sep 17, 2026 4 Filing
Sep 16, 2026 3 Filing
Sep 14, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Jul 31, 2026 8-K Current Report
View All SEC Filings ➞
INmune Bio
INmune Bio logo
Country United States
IPO Date Feb 4, 2019
Industry Biotechnology
Sector Healthcare
Employees 21
CEO David J. Moss

Contact Details

225 NE Mizner Boulevard Boca Raton, Florida 33432 United States

Stock Details

Ticker Symbol INMB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001711754
CUSIP Number 45782T105
ISIN Number US45782T1051
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.